Particle Therapy Cooperative Group - North America

What Particle Therapy Cooperative Group - North America does

Particle Therapy Cooperative Group - North America (PTCOG-NA) is a non-profit professional society founded in January 2013 in Flint, Michigan, operating as the North American chapter of the international Particle Therapy Cooperative Group (PTCOG), which was established as a Swiss non-profit Association in 2007. The society's stated mission is to enhance collaboration among physicians, physicists, biologists, engineers, and dosimetrists working in particle therapy, create a platform for scientific exchange, and develop treatment guidelines, education, and training initiatives for particle radiotherapy in cancer care. PTCOG-NA also takes steps toward establishing particle therapy clinical trial collaborative groups, representing the field in industrial technology and healthcare policy, and improving relationships with other radiation oncology professional societies. The organization co-owns the International Journal of Particle Therapy, established in 2014 with Elsevier as publishing partner since January 2024.

PTCOG-NA's product surface is built around four offerings: an annual scientific meeting (10th held in New York in 2024, with meetings scheduled through Washington DC in 2026 and a joint PTCOG meeting in Jacksonville, FL in 2028), an online membership portal providing access to past meeting materials and resources, periodic newsletters, and topic-specific symposia (e.g., 2020 thoracic/particle therapy for lung cancer symposium). A dedicated mobile app supports annual meeting program navigation, scheduling, and exhibitor engagement. Underlying technology is administrative rather than proprietary — a self-serve web portal, a third-party registration platform (CZECH-IN s.r.o.), and standard CRM/membership tooling. No patents, proprietary software, or AI/ML capabilities are disclosed in the input data.

The revenue model is a hybrid of low-fee annual membership dues (Full $225, Associate $125, In-Training free) and per-event conference registration ($330-$765 tiered by membership status and timing). Sponsorship and exhibition income from industry partners (IBA as Platinum; Varian, RaySearch, P-Cure, CQ Medical as Gold/Bronze tiers; Elsevier as media partner) supplements this base. The go-to-market motion is community-led, with member acquisition and renewal driven through annual conferences, scientific symposia, and the online membership portal. End customers are individual radiation oncology, medical physics, biology, engineering, and dosimetry professionals; institutional stakeholders include ~30+ U.S. proton therapy centers such as Mayo Clinic, MD Anderson, Massachusetts General, New York Proton Center, and Fred Hutchinson Cancer Center. Headcount is reported at 1-10, with no funding rounds, parent control resting with PTCOG, and no disclosed revenue or financial statements.

Name

Particle Therapy Cooperative Group - North America

Legal name

Particle Therapy Co-Operative Group Chapter of North America

Website

https://ptcog-na.org

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Particle Therapy Cooperative Group - North America (PTCOG-NA) is a non-profit professional society, founded 2013, that advances particle radiotherapy through annual scientific conferences, membership services, and the International Journal of Particle Therapy for radiation oncologists, physicists, biologists, engineers, and dosimetrists across North America.

Ownership category

akta.pro rank

Headquarters

HQ city

Rochester

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership Dues: Annual membership fees provide recurring revenue. Membership categories include Full ($225), Associate ($125), and In Training (free). Membership provides access to online portal, meeting materials, newsletters, and voting rights.
2. Annual Meeting Registration: Registration fees for annual conferences range from $330-$765 depending on membership status and registration timing. Additional revenue from optional extras including gala dinners, facility tours, and industry sponsorships.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

PTCOG-NA is a non-profit professional society that advances particle (primarily proton) therapy for cancer treatment in North America by facilitating scientific exchange among clinicians, physicists, and researchers. It delivers annual scientific meetings, continuing education and CME programs, develops treatment and clinical practice guidelines, and supports collaborative research across the limited number of operating particle therapy centers in the region.

Product overview

PTCOG-NA is a non-profit professional society (membership organization), not a product company. It operates as the North American chapter of the international Particle Therapy Cooperative Group (PTCOG). Its offerings include annual scientific conferences, a membership portal with access to meeting materials and resources, newsletters, educational symposia, and support for clinical trial collaborative groups in particle therapy. The society collaborates with PTCOG to publish the International Journal of Particle Therapy.

Differentiator

Problem solved

Functional benefit

Products and services

• PTCOG-NA Membership

Quantifiable outcome

• Established International Journal of Particle Therapy in 2014 in collaboration with PTCOG

Named customers6 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

24 partnerships are on record, tiered core, strategic, standard and minor.

• International Journal of Particle Therapy (IJPT)coreStrategic or Co-development Partner · 1 January 2014PTCOG-NA, in collaboration with PTCOG, helped establish the International Journal of Particle Therapy in 2014. Elsevier became the proud publishing partner as of January 1, 2024. The journal provides a preferred venue for disseminating clinical, physical, and biological research in proton and particle therapy.
• Particle Therapy Cooperative Group (PTCOG)coreStrategic or Co-development Partner · 1 January 2013PTCOG-NA is the North American chapter of the international Particle Therapy Cooperative Group (PTCOG). PTCOG is an international non-profit organization founded in 1985 and established as a non-profit Association under Swiss law in 2007. The organizations collaborate on scientific exchange, treatment guidelines, and education initiatives. PTCOG owns the International Journal of Particle Therapy.
• Fred Hutchinson Cancer CentercoreStrategic or Co-development PartnerFred Hutchinson Cancer Center (Fred Hutch) served as local host for the 2021 Seventh Annual Conference and 9th Annual Conference (2023). Fred Hutch Cancer Center Proton Therapy Center has been in operation since 2013 and treated approximately 540 patients per year. The center conducts research on FLASH and ocular treatments.
• University of Washington School of MedicinecoreStrategic or Co-development PartnerUniversity of Washington School of Medicine was the local host for the 2021 Seventh Annual Conference along with Fred Hutch. Ramesh Rengan, MD, PhD serves as Professor and Chair of Radiation Oncology and Medical Director of SCCA Proton Therapy Center.
• New York Proton CentercoreStrategic or Co-development PartnerNew York Proton Center was the local host for the 10th Annual Meeting (2024). Opened in August 2019, NYPC has treated over 5,000 patients in its first 5 years. The center offers FLASH-enabled research and clinical applications.
• IBA Proton TherapystrategicGTM or Marketing PartnerIBA is a worldwide innovation leader in proton therapy, offering DynamicARC and ConformalFLASH technologies on their Proteus platform. They have treated over 130,000 patients globally. Served as Platinum Partner at 9th and 10th Annual Conferences and hosts industry symposia.
• Varian, A Siemens Healthineers CompanystrategicGTM or Marketing PartnerVarian provides imaging and cancer care technologies. Served as Gold Partner at 9th Annual Conference and exhibitor at 10th Annual Meeting. Hosts industry symposium on expanding access to proton therapy.
• RaySearch LaboratoriesstrategicGTM or Marketing PartnerRaySearch develops software solutions for cancer treatment including RayStation treatment planning system, RayCare oncology information system, and RayIntelligence analytics system. Gold Partner at 9th and 10th Annual Conferences.
• Mevion Medical SystemsstandardGTM or Marketing PartnerLeading provider of compact proton therapy systems. Pioneered single-room platform with MEVION S250i and MEVION S250-FIT with HYPERSCAN pencil beam scanning. Bronze Partner at 10th Annual Conference.
• P-Cure LtdstrategicGTM or Marketing PartnerP-Cure offers compact FDA-cleared proton therapy solution for treating cancer patients. Gold Partner at 10th Annual Conference. System enables planning and treatment in both supine and seated positions.
• Proton Collaborative GroupcoreStrategic or Co-development PartnerPCG is committed to improving cancer patient outcomes by advancing particle radiotherapy. Serves as link between treatment centers, expert physicians, collaborative research, and maintains proton therapy database. Exhibitor at Annual Meetings.
• Vision RTstandardTechnology or IntegrationInventors and market leaders in Surface Guided Radiation Therapy (SGRT). Systems in active clinical use in more than 2,000 clinics globally. Bronze Partner at 10th Annual Conference.
• Gold AnchorstandardTechnology or IntegrationFiducial marker for soft tissue with thin diameter, great kV-visibility, and MR-visibility. Bronze Partner at 10th Annual Conference. Industry-leading thin needle options (25G, 22G or 20G).
• OrfitstandardTechnology or IntegrationProvides high precision positioning and immobilization devices for proton therapy including Aerial proton couch top and Nanor masks. Bronze Partner at 10th Annual Conference.
• RAD Technology Medical SystemsstandardTechnology or IntegrationProvides design-built modular facilities for healthcare including radiotherapy and proton vaults. Solutions completed up to 50% faster than standard construction. Bronze Partner at 10th Annual Conference.
• CosylabstandardTechnology or IntegrationLeading provider of software solutions for medical devices and cancer therapy systems. Specializes in particle therapy software from accelerator control to treatment control systems. Bronze Partner at 10th Annual Conference.
• HitachistandardTechnology or IntegrationLeading provider of synchrotron-based proton/carbon/hybrid particle therapy systems with long history of successful installations. Currently working on three projects in the United States. Bronze Partner at 10th Annual Conference.
• SDX SystemstandardTechnology or IntegrationVoluntary breath-hold device with direct lung volume measurement and bio-visual feedback for lung, liver, and thoracoabdominal treatments. Used in 18 Proton Therapy Centers in the US. Partner at 10th Annual Conference.
• CQ MedicalstandardTechnology or IntegrationGlobal leader in radiotherapy and cancer therapy solutions with over 80 years combined experience. Provides patient immobilization, positioning, fiducial markers, and couchtops. Gold Partner at 9th Annual Conference.
• ElsevierstrategicGTM or Marketing PartnerGlobal information analytics company and proud publishing partner of PTCOG since January 1, 2024. Publishes the International Journal of Particle Therapy. Media Partner at 10th Annual Conference.
• PhysicsWorldminorGTM or Marketing PartnerMedia Partner at 10th Annual Conference. Provides science communications and coverage of physics topics.
• C4 ImagingstandardTechnology or IntegrationPioneers MRI-positive signal markers including NOVA for treatment alignment and Sirius/Orion for LDR/HDR therapy. Exhibitor at 9th Annual Conference.
• KlaritystandardTechnology or IntegrationProvider of radiotherapy technology including patient positioning, treatment planning, brachytherapy, and custom devices. Gold Partner at 9th Annual Conference.
• DYN'R US Inc.standardTechnology or IntegrationProvider of SDX System in US for respiratory gating. Integrates with IBA Proteus, Mevion S250i, and Varian Probeam for beam synchronization. Gold Partner at 9th Annual Conference.

Scale indicators3 records

Recent moves2 records

Expansion highlights4 records

Direct peers

• American Brachytherapy Society (ABS): A U.S. professional society dedicated to brachytherapy. ABS is a smaller, modality-specific radiotherapy society structurally similar to PTCOG-NA, with comparable membership and annual meeting models targeting overlapping dosimetrist and physicist communities.
• American Association of Physicists in Medicine (AAPM): A U.S. professional society for medical physicists. AAPM overlaps significantly with PTCOG-NA's medical physicist member segment on treatment planning, dosimetry, and quality assurance, and provides competing continuing education credits (CAMPEP) relevant to particle therapy practice.
• European Society for Radiotherapy and Oncology (ESTRO): A European non-profit professional society for radiation oncology. ESTRO serves a parallel function to PTCOG-NA in its region, with annual congresses, educational programs, and member accreditation that directly substitute for what PTCOG-NA offers its North American members.
• Proton Collaborative Group (PCG): A U.S. non-profit dedicated to advancing particle radiotherapy through clinical research. PCG maintains a proton therapy database and exhibits at PTCOG-NA meetings, with overlapping mission around clinical trial coordination and treatment center collaboration.
• Particle Therapy Cooperative Group (PTCOG): The parent international organization of PTCOG-NA. PTCOG is the global non-profit for particle therapy professionals, sharing the same scientific mission, journal ownership, and member community focus as PTCOG-NA but operating globally rather than regionally.

Broad incumbents

• American Society for Radiation Oncology (ASTRO): The largest U.S. professional society for radiation oncology. ASTRO serves a similar member base (radiation oncologists, physicists, dosimetrists) and competes for educational programming, conference attendance, and journal readership, though it covers all radiotherapy modalities rather than specializing in particle therapy.
• Radiological Society of North America (RSNA): A large radiology and radiation oncology professional society with a major annual meeting. RSNA competes broadly for clinician CME time and sponsorships, though its focus is broader imaging and radiation rather than particle therapy specifically.
• American Society of Clinical Oncology (ASCO): The largest U.S. professional society for oncology broadly. ASCO overlaps with PTCOG-NA at the radiation oncology interface and offers broader oncology content; while not a direct competitor on particle therapy specifically, it captures mindshare and CME spend from the same clinicians.

Emerging players

• Society for Translational Oncology: A smaller professional society bridging research and clinical oncology practice. STO has overlapping educational programming for clinicians interested in emerging oncology modalities and could compete for niche conference participation.
• International Association for the Study of Lung Cancer (IASLC): A global professional society focused on thoracic oncology. IASLC partnered with PTCOG-NA on thoracic particle therapy symposia (e.g., 2020 Lung Cancer Symposium), competing for attention in the lung cancer particle therapy subsegment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/PTCOGNA
• LinkedInlinkedin.com/company/ptcog-na

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Particle Therapy Cooperative Group - North America